Clinical Trials & Research
Leading Research. Promising Drug Trials.
Over the past 40 years, Ocala Oncology/Florida Cancer Affiliates has provided our patients access to cutting-edge and innovative clinical trials in a comfortable and convenient setting. One of the largest and most reputable community-based research networks in the world, US Oncology Research has contributed to over 70 FDA-approved cancer therapies and approximately one-third of all FDA-approved oncology therapies. It also specializes in Phase I–IV oncology clinical trials and has participated in over 1,600 investigator-initiated and sponsor-initiated trials since its inception. The program brings innovative therapies and clinical trials to practices and patients in communities across the nation to help advance the science of cancer care while offering the best possible treatments and improved patient outcomes.
We are proud of our new role in the research and development of vital new cancer therapies through independent studies. This will alow us broader range of opportunities to offer our patients . We are dedicated to advancing cancer care by leading and participating in clinical trials that test the safety and efficiency of new or modified treatments. And we are deeply committed to bringing clinical trials to our community, offering patients an opportunity to help shape the future of cancer treatment, while benefitting from the very latest in clinical trials. Ocala Oncology/Florida Cancer Affiliates is constantly offering eligible patients opportunities to join new trials.
At Ocala Oncology/Florida Cancer Affiliates,research is an integral part of our comprehensive efforts to provide cancer patients in our community with access to the latest and most advanced therapies and treatment options. We now have access to Sarah Cannon Research Trials.
We are pleased to share this list of clinical trials currently enrolling at our practice.
MYLUNG Consortium™ research study in metastatic non-small cell lung cancer (mNSCLC)
I am pleased to share an update regarding our progress with the MYLUNG Consortium™ research study in metastatic non-small cell lung cancer (mNSCLC). Results from the first phase were released during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting by The US Oncology Network (The Network), US Oncology Research and Ontada™.
Makenzi Evangelist, MD, physician lead for the study and oncologist with New York Oncology Hematology, presented the findings during an oral presentation at ASCO titled, “Biomarker tissue journey among patients with untreated metastatic non-small cell lung cancer (mNSCLC) in The US Oncology Network community practices.” (ASCO Abstract 9004)
Protocol 1 (out of 3) provides a retrospective look at chart data and allows us to draw early conclusions about historical baseline trends for testing patterns and identify gaps in the data that need to be filled with the prospective research the MYLUNG Consortium will address in the next protocol.
Protocol 1 findings include:
- Most patients had at least one biomarker test result prior to first-line therapy
- Fewer than 50% of patients had all five available biomarker tests
- The median time from diagnosis to first-line therapy is about five weeks
Data from Protocol 1 will be compared to Protocol 2, which will prospectively evaluate contemporary ordering patterns and turnaround times. It will enroll about 1,000 patients from 11 sites across The Network and will monitor the real-world patient journey from presentation through their first line of cancer therapy, focusing on how diagnostic biomarker information is obtained, utilized and operationalized in decision-making. Patients are currently being enrolled in this stage of the study.
In addition to recognizing the progress that’s been made through this innovative research, I want to acknowledge the growing number of consortium participants and welcome two new life science companies. Genentech and AstraZeneca have joined this collaborative effort along with current members Amgen, Eli Lilly and Company and Mirati Therapeutics.
We will continue to grow the MYLUNG Consortium to reach up to 7,500 patients from approximately 20 Network sites over a five-year period during Protocol 3, integrating findings from the previous protocols and exploring new processes and associated outcomes. Thank you to the participating physicians and patients – together we are enabling providers to make the best treatment recommendations while improving access to testing and therapies for patients with lung cancer.
For more information, visit the MYLUNG webpage and blog on usoncology.com
TOP ENROLLING CLINICAL TRIAL SITE IN THE UNITED STATES
Congratulation to Dr. Ketan Doshi and the research team at Ocala Oncology/Florida Cancer Affiliates for being recognized as the top enrolling site in the United States for a Follicular Lymphoma study evaluating patients receiving the combination of Ibrutinib and Rituximab for the treatment of follicular lymphoma. View Clinical Trials
